Back

Effects of interleukin 6 inhibitor tocilizumab on endothelial glycocalyx, vascular and myocardial function compared to prednisolone.

2 September 2019 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Chronic inflammatory diseases Autoimmune/Chronic Inflammatory Disorders and Heart Disease ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Ignatios Ikonomidis

National & Kapodistrian University of Athens, Athens (Greece)

7 More presentations in this session

Presentation thumbnail
Doctor K. Kakuta (Yokkaichi, JP)
Abstract Slides
Presentation thumbnail
Doctor B. Logstrup (Aarhus, DK)
Abstract
Presentation thumbnail
Doctor D. Novikova (Moscow, RU)
Abstract Slides
Presentation thumbnail
Doctor M. Wamil (Oxford, GB)
Abstract Slides
Presentation thumbnail
Doctor A. Rimouche (Brussels, BE)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 5 - Chronic inflammatory diseases

The Event

Event poster

ESC Congress 2019

2 September 2019 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Inhibition of interleukin-6 by tocilizumab improves endothelial glycocalyx and myocardial work index in patients with rheumatoid arthritis
28 August 2020
thumbnail
Congress Presentation
The role of cardiometabolic risk factors and endothelial dysfunction in serum albumin levels and capillary leak syndrome of patients with COVID-19
29 August 2022
thumbnail
Congress Presentation
The effects of empagliflozin on arterial stiffness, endothelial function and ventriculoarterial coupling in type 2 diabetes mellitus: 1 year follow up
31 August 2020
thumbnail
Congress Presentation
Proinflammatory status, vascular wall morphofunctional state and relative associations in patients with lymphomas before chemotherapy
13 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources